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Abstract
The aim of this prospective cohort study was to determine the risk factors for community-acquired urinary tract infections (UTIs)
caused by extended-spectrum b-lactamase (ESBL)-positive Escherichia coli and the distribution of the ESBL enzyme types. Structured
forms were ﬁlled in for patients diagnosed with community-acquired UTI in four different geographical locations in Turkey. The forms
and the isolates were sent to the central laboratory at Baskent University Hospital, Ankara. Antimicrobial susceptibility was determined
according to the CLSI criteria. PCR and DNA sequencing were used to characterize the blaTEM, blaCTX-M and blaSHV genes. Multivariate
analysis was performed using logistic regression. A total of 510 patients with UTI caused by Gram-negative bacteria were included in
this study. ESBLs were detected in 17 of 269 (6.3%) uropathogenic E. coli isolates from uncomplicated UTIs and 34 of 195 (17.4%)
E. coli isolates from complicated UTIs (p <0.001). According to multivariate analysis, more than three urinary tract infection episodes in
the preceding year (OR 3.8, 95% CI 1.8–8.1, p <0.001), use of a b-lactam antibiotic in the preceding 3 months (OR 4.6, 95% CI 2.0–0.7,
p <0.001) and prostatic disease (OR 9.6, 95% CI 2.1–44.8, p 0.004) were found to be associated with ESBL positivity. The percentages
of isolates with simultaneous resistance to trimethoprim–sulphamethoxazole, ciproﬂoxacin and gentamicin were found to be 4.6% in the
ESBL-negative group and 39.2% in the ESBL-positive group (p <0.001). Forty-six of 51 ESBL-positive isolates (90.2%) were found to har-
bour CTX-M-15. Therapeutic alternatives for UTI, particularly in outpatients, are limited. Further clinical studies are needed to guide
the clinicians in the management of community-acquired UTIs.
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Introduction
The incidence of community-acquired urinary tract infections
(UTIs) due to extended-spectrum b-lactamase (ESBL)-
producing Escherichia coli has increased worldwide [1,2].
Recently, the emergence of an intercontinental clone of an
E. coli strain producing CTX-M-15 has gained much interest,
and Turkey was reported to be concerned by this emer-
gence of a community-acquired urinary isolate [3–5]. Besides
their capacity for rapid and widespread dissemination, ESBL-
producing strains are increasingly associated with resistance
to non-b-lactam antimicrobials, and cause therapeutic
difﬁculties for outpatients [6].
The aim of this prospective cohort study was to deter-
mine the risk factors for ESBL positivity in community-
acquired uropathogenic E. coli strains and the distribution of
the enzyme types.
Materials and Methods
Design of the study
The present study is a prospective cohort study, and was
carried out between 1 January 2007 and 31 December 2007.
Patients with the diagnosis of UTI were included consecu-
tively. UTI was deﬁned as a growth of 105 CFU/mL in urine
culture, pyuria, and at least one of the following symptoms:
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dysuria, frequency or urgency. Each patient was included
once in the study, and only one isolate was obtained from
each patient. The four centres participating in the study were
located in large cities from three geographically distinct
regions of Turkey. All four centres were tertiary-care hospi-
tals of Bas¸kent University. In Turkey, patients may be admit-
ted to any hospital (primary-care or tertiary-care hospital)
with any complaint (including dysuria), because there is not
yet an admission chain scheduled in the healthcare system. In
this way, consecutive outpatients admitted to the participat-
ing centres were included in this study.
Data collection
A structured form was used to collect data about demo-
graphic characteristics, urinalysis, signs of complication, anti-
biotic usage, and underlying diseases. Informed consent from
participants was obtained on a written form. All forms and
the identiﬁed Gram-negative uropathogens were sent to the
central laboratory (Baskent University Ankara Hospital
Microbiology Laboratory). This project was approved by the
Bas¸kent University Research Committee and was funded by
Bas¸kent University Research Foundation.
Patients
Patients between 18 and 65 years of age with the diagnosis
of community-acquired uncomplicated or complicated UTI
were included in the study. Uncomplicated UTI is deﬁned as
an infection in a structurally and neurologically normal
urinary tract [7]. Complicated UTI is deﬁned as an infection
in a urinary tract with functional or structural abnormalities,
and UTI in men and pregnant women [7]. Male patients with
urolithiasis, patients who had more than three episodes of
UTI in the preceding year, pregnant patients, patients with a
urinary catheter and patients who had undergone an opera-
tion because of urolithiasis or bladder malignancy in the pre-
ceding year were considered to have complicated UTI.
Hospital stay within the preceding month was a criterion of
exclusion.
Laboratory methods
Standard biochemical reactions were performed as the ﬁrst
step for the identiﬁcation of bacteria, and BBL Crystal
Enteric/NF 4.0 identiﬁcation kits (Becton Dickinson) were
used when needed. All isolates were stored at )20C. Anti-
biotics were grouped into two sets according to the require-
ments of clinical practice; one was tested against isolates
from uncomplicated UTIs, and the other against isolates from
complicated UTIs. The antibiotics tested against both types of
isolate were ampicillin, amoxycillin–clavulanate, cefazolin,
cefuroxime, ceftriaxone, ceﬁxime, gentamicin, ciproﬂoxacin,
trimethoprim–sulphamethoxazole, imipenem, meropenem,
and ertapenem. The antibiotics tested only against isolates
from uncomplicated UTIs were nitrofurantoin and fosfomycin.
The antibiotics tested only against isolates from complicated
UTIs were piperacillin–tazobactam, cefepime, cefoperazone,
ceftazidime, and amikacin.
Antibacterial susceptibility testing was performed accord-
ing to the CLSI criteria [8]. Quality control was ensured
by testing E. coli ATCC 25922, Pseudomonas aeruginosa
ATCC 27853 and ESBL-producing Klebsiella pneumoniae
ATCC 700603 in every batch. All zone sizes for these strains
were within the ranges given by the CLSI for the antibiotics
tested in this study. ESBL determination was performed
phenotypically with ceftazidime/ceftazidime clavulanate and
cefotaxime/cefotaxime clavulanate disks, as recommended by
the CLSI [8].
Characterization of enzyme types
PCR and DNA sequencing were used to characterize the
blaTEM, blaCTX-M and blaSHV genes. DNA sequencing was per-
formed with the DYEnamic ET Terminator Cycle Sequencing
Kit (Amersham Biosciences Corp., NJ, USA) and an ABI
PRISM 310 Genetic Analyzer at Iontek Ltd, Turkey. The
primers used have been described previously [9].
Statistical methods
Data were analysed using the SPSS (version 11.0) software
package. Categorical variables were compared using chi-
square tests, although Fisher’s exact test was used when data
were sparse. Signiﬁcance was set at p <0.05, using two-sided
comparisons. A multivariate model was used. Multivariate
analysis included age, gender, and all signiﬁcant factors found
in univariate analysis. Signiﬁcance was set at p <0.05 for inclu-
sion in the multivariate analysis. A backward stepwise method
was used for the elimination of the risk factors. ESBL positiv-
ity was the dependent variable in logistic regression.
Results
A total of 16 130 urine samples were submitted to the
microbiology laboratories of four centres during the 1-year
study period. A total of 510 patients were included in this
study. E. coli was isolated from 464 (90%) patients, and Klebsi-
ella spp. were isolated from 27 (5%) patients. The mean age
was 43 years, with a range of 18–65 years. E. coli was the
causative agent in 269 of 289 (93%) uncomplicated UTIs and
in 195 of 221 (88%) complicated UTIs (p 0.05).
ESBL positivity was detected in 17 of 269 (6.3%) uropath-
ogenic E. coli strains isolated from uncomplicated UTIs and in
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34 of 195 (17.4%) E. coli strains isolated from complicated
UTIs (p <0.001). The rates of resistance in E. coli strains
against the tested antibiotics are shown in Table 1.
The results of the univariate analysis are shown in Table 2.
Multivariate analysis included all signiﬁcant factors found in uni-
variate analysis (more than three UTI episodes in the preced-
ing year, prostatic disease, UTI in the preceding year, use of a
b-lactam antibiotic in the preceding 3 months), and revealed
that more than three UTI episodes in the preceding year
(OR 3.8, 95% CI 1.8–8.1, p <0.001), use of b-lactam antibiotics
in the preceding 3 months (OR 4.6, 95% CI 2.0–10.7,
p <0.001) and prostatic disease (OR 9.6, 95% CI 2.1–44.8,
p 0.004) were associated with ESBL positivity. The Hosmer
and Lemeshow test (p 0.807) was used as a goodness-of-ﬁt
measure.
The rates of ciproﬂoxacin resistance among ESBL-positive
and ESBL-negative strains were 84% and 23%, respectively
(p <0.001); the corresponding values for trimethoprim–
sulphamethoxazole resistance were 69% and 39% (p <0.001),
for gentamicin resistance they were 57% and 9% (p <0.001),
and for amoxycillin–clavulanate resistance they were 76%
and 13% (p <0.001).
Multidrug resistance, deﬁned as resistance to at least two
of trimethoprim–sulphamethoxazole, ciproﬂoxacin or genta-
micin, was seen in 21.1% of E. coli isolates in the ESBL-nega-
tive group and in 70.6% in the ESBL-positive group
(p <0.001). Isolates resistant to all three antibiotics were
found at a rate of 4.6% in the ESBL-negative group and
39.2% in the ESBL-positive group (p <0.001).
Forty-six of 51 ESBL-positive isolates (90.2%) were found
to harbour CTX-M-15, four isolates harboured CTX-M-3,
and the remaining isolate harboured SHV-12. Six of 46 CTX-
M-15-positive isolates also harboured TEM-116.
Discussion
ESBL-producing E. coli has become the most worrisome
causative agent of community-acquired UTIs. The present
study is a prospective cohort study evaluating the prevalence
of and risk factors for both uncomplicated and complicated
UTIs. ESBL positivity was detected in 6.3% of E. coli isolates
from uncomplicated UTIs and in 17.4% of E. coli isolates from
complicated UTIs. More than three UTIs in the preceding
year, use of a b-lactam antibiotic in the preceding 3 months
and prostatic disease were found to be associated with ESBL
positivity. One of the most striking ﬁndings of this study is
the high rate of resistance to other drug classes; that is,
39.2% of ESBL-producing isolates were found to be resistant
to trimethoprim–sulphamethoxazole, ciproﬂoxacin and
gentamicin. CTX-M-15 was the most common (90.2%) ESBL
type harboured by uropathogenic E. coli strains.
In our previous study carried out in 2004, ESBL positivity
was found to be 5% in isolates from uncomplicated UTIs and
12% in isolates from complicated UTIs [10]. The same
increasing trend was observed in Spain [11]. Recurrent UTI, a
major risk factor determined in our study, was also found to
be an independent risk factor for ESBL positivity in two other
studies from Spain [1,7]. Previous use of aminopenicillins [1],
cephalosporins [1], cefuroxime [11], second-generation and
third-generation cephalosporins [12], penicillins [12] or ceph-
alosporins [13] was associated with ESBL positivity in other
TABLE 1. Rates of resistance to antimicrobial agents in
uropathogenic Escherichia coli isolates
Uncomplicated
UTI,
n = 269 (%)
Complicated
UTI,
n = 195 (%) p
Ampicillin 143 (53) 129 (66) 0.005
Amoxycillin–clavulanic acid 39 (14) 52 (27) 0.001
Cefazolin 39 (14) 49 (25) 0.004
Cefuroxime 38 (14) 48 (25) 0.004
Ceftriaxone 25 (9) 36 (18) 0.004
Ceﬁxime 25 (9) 36 (18) 0.004
Gentamicin 28 (10) 38 (19) 0.006
Ciproﬂoxacin 59 (22) 80 (41) <0.001
Trimethoprim–sulphamethoxazole 93 (35) 98 (50) 0.001
Nitrofurantoina 3 (1) –
Fosfomycina 1 (<1) –
Cefoperazoneb – 34 (17)
Ceftazidimeb – 18 (9)
Amikacinb – 11 (6)
Piperacillin–tazobactamb – 9 (5)
Cefepimeb – 27 (14)
UTI, urinary tract infection.
aTested only for isolates from uncomplicated UTIs.
bTested only for isolates from complicated UTIs.
TABLE 2. Univariate analysis of extended-spectrum b-lac-
tamase (ESBL) positivity among uropathogenic Escherichia
coli
Total,
n = 464 (%)
ESBL
positivity,
n = 51 (%) p
Age over 50 years 161 (35) 18 (11) 0.925
Complicated UTI 195 (42) 34 (17) <0.001
Male gender 59 (13) 9 (15) 0.262
Urolithiasis 45 (10) 9 (20) 0.073
Pregnancy 20 (4) 1 (5) 0.712
Urological operation 28 (6) 6 (21) 0.108
Prostatic disease 7 (2) 3 (42) 0.032
More than three UTI
episodes in the preceding year
47 (10) 14 (30) <0.001
Urinary catheter 16 (3) 2 (13) 0.692
UTI in the preceding year 125 (27) 22 (18) 0.006
Use of antibiotic in the preceding
3 months
91 (20) 19 (21) 0.001
Use of b-lactam antibiotic
in the preceding 3 months
31 (7) 11 (35) <0.001
Use of quinolones in the preceding
3 months
29 (6) 3 (10) 1.000
UTI, urinary tract infection.
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studies. Quinolone use was found to be an independent risk
factor in many studies, including one from Turkey [1,7,12,13],
but was not found to be associated with ESBL positivity in a
recent study, just as in the present study [11]. This is some-
what surprising, because misuse of quinolones along with
other antibiotics was documented in a study from Turkey
[14]. Long-term-care facilities were found to be risk factors in
other studies but, as nursing home care is not common in
Turkey, no long-term-care facility was included in this study.
One of the most worrisome aspects of ESBL-positive bac-
teria concerns the high rates of resistance to non-b-lactam
antibiotics, particularly quinolones, trimethoprim–sulphameth-
oxazole, and aminoglycosides. Ciproﬂoxacin resistance, in a
study from Spain in 2006, was reported to be 31.5% in ESBL-
positive and 9.1% in ESBL-negative E. coli isolates [11]. Cipro-
ﬂoxacin resistance rates, published in 2004 from Israel, were
reported to be even higher: 39% in ESBL-positive and 16% in
ESBL-negative E. coli isolates [12]. The results of the present
study show an unfortunately high rate, 84%, of ciproﬂoxacin
resistance among ESBL-positive E. coli isolates. Multidrug-
resistant isolates, which cause difﬁcult-to-treat infections, are
also increasing in parallel. In a study from Spain, the percent-
age of multidrug-resistant isolates was reported to be higher
than 70%, similar to the rate of 70.6% found in our study [11].
The most important consequence of such high resistance
rates is the ensuing difﬁculty in the management of UTI
patients. The number of drugs available for use in the outpa-
tient setting is limited. Nitrofurantoin and fosfomycin seem
to be the only choices in appropriate cases. Fortunately, in
the present study, only three of all 464 uropathogenic E. coli
isolates were resistant to nitrofurantoin, and only one isolate
was resistant to fosfomycin, which is similar to what has
been observed in many other studies [1,10,15,16]. Amoxycil-
lin–clavulanate was used with success for patients with cysti-
tis due to ESBL-producing E. coli in a recent study [1] where
the resistance rate was 29%, and for lower urinary tract
infection according to one case report [17], but as 76% of
our ESBL-positive isolates were found to be resistant, this
does not seem to be a good choice in our region.
The ﬁrst CTX-M-15-producing E. coli isolate from Turkey
was reported in 2005 and was isolated from the urine of a
hospitalized patient [18]. In a recent study from Turkey,
CTX-M-15 was found in 53% of uropathogenic E. coli isolates
from community-acquired UTIs [6]. This increase in the fre-
quency of CTX-M-15 in such a short period should be taken
note of by clinicians.
The ESBL positivity and ciproﬂoxacin resistance rates are
higher than those reported in other studies. One of the
reasons for these high rates is that data were obtained from
tertiary-care facilities. Another reason is probably related to
the deﬁnition of ‘community-acquired’ infections, because, as
stated by Friedman et al. [19], there seems to be a need to
change the term ‘community-acquired’ to ‘healthcare-
associated’, particularly in some instances. Therefore, our
estimates regarding the resistance rates might be exagger-
ated, because we considered both tertiary-care admissions
and healthcare-associated infections.
In conclusion, the widespread and rapid dissemination of
ESBL-producing uropathogenic E. coli seems to be an emerg-
ing issue worldwide. Further clinical studies are needed to
guide clinicians in the management of community-acquired
UTI cases.
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